Healio.com: FDA fast tracks novel autism drug

J. Thomas Megerian

The FDA recently granted fast track designation status to the tyrosine hydroxylase inhibitor known as L1-79, a potential treatment for autism, according to a press release from Yamo Pharmaceuticals, the drug’s manufacturer.

“The only autism spectrum disorder treatments that are approved are for agitation and

Read the full article at the original source

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.